The Terrible, Horrible, No Good, Very Bad Pharma Day*
A challenge You are passionate about providing an intervention (drug or device) to a group…
None Better than One? (A Brief Note on VC in Smaller Hubs)
Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment…
Blood: Underappreciated Resource in the Health/Disease?
Alternative title: Pitching a VC on Disruption of Blood Testing You may have seen…
#MHVF Approaches to Drug Development
Today I had the chance for a panel conversation with Geeta Vemuri from Baxter Ventures…
Precision in Oncology: Using the Macro and Micro
Last week, the New York Times had a nice piece "A Faster Way to…
Case Study: When does “technology” turn into medical device
This semester I've embarked on an adventure to co-teach a class in the University…
What is the optimal biotech burn rate?
Ethan Perlstein, founder of Perlstein Lab, asked a question on Twitter and got some great…
We All Need a Risk Framework
I recently read “The Most Important Thing Illuminated: Uncommon Sense for the Thoughtful Investor”…
Supporting Biotech Development in Madison
As part of our follow up to our recent Biotech in Wisconsin Meetup about…
How Could Science #BreaktheInternet?
I saw the Breakthrough Prizes announced this weekend and was excited to learn about…
Load More